A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT05147805
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 102 participants
- Sponsor
- Registry
-
NCT05147805 -
2021-001528-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Denmark, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Serbia, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05147805. Randomized; double masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2025-03-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Treprostinil Palmitil
- Intervention (Drug)
- Placebo
- Lead sponsor
- Insmed Incorporated
Record details
- Record id
cardio:ct-nct05147805- Content hash
75c167fc82c7a73abc2cc496503dc054f43c871fcca9582d03177e9895554884